Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells

Anti-Cancer Drugs

Volumn 8, Issue 2, 1997, Pages 199-203

  Asakura, Tadashi ^a   Takahashi, Naoto ^a   Takada, Koji ^a   Inoue, Takahiro ^a   Ohkawa, Kiyoshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Doxorubicin; Glutathione; Multidrug resistance; P glycoprotein; Rat hepatoma cell

Indexed keywords

BOVINE SERUM ALBUMIN; DOXORUBICIN; DOXORUBICIN DERIVATIVE; GLUTATHIONE; GLYCYLGLYCINE; MULTIDRUG RESISTANCE REVERSING AGENT; PEPTIDE; TRIGLYCINE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG MECHANISM; HEPATOMA CELL; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031046486     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199702000-00011     Document Type: Article

References (14)

1. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
2. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316: 817-9.
3. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42: 4730-3.
4. Twentyman PR, Fox NE, White DJG. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. Br J Cancer 1987; 56: 55-7.
5. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 1991; 51: 6039-44.
6. FitzGerald DJ, Willingham MC, Cardarelli CO, et al. A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 1987; 84: 4288-92.
7. Tsuruo T, Hamada H, Sato S, Heike Y. Inhibition of multidrug-resistant human tumor growth in athymic mice by anti-P-glycoprotein monoclonal antibodies. Jpn J Cancer Res 1989; 80: 627-31.
8. Pearson JW, Fogler WE, Volker K, et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991; 83: 1386-91.
9. Ohkawa K, Hatano T, Yamada K, et al. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 1993; 53: 4238-42.
10. Ohkawa K, Hatano T, Tsukada Y, Matsuda M. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro. Br J Cancer 1993; 67: 274-8.
11. Hatano T, Ohkawa K, Matsuda M. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro. Tumor Biol 1993; 14: 288-94.
12. Takahashi N, Asakura T, Ohkawa K. Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells. Anti-Cancer Drugs 1996; 7: 687-96.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Method 1983; 65: 55-63.
14. Tata JR. Biomembrane, Part A. Methods Enzymol 1974; 31: 253-62.